BD invests €4 million into a new R&D facility and €30 million in a manufacturing facility

BD (Becton, Dickinson and Company) is a leading global medical technology company that focuses on advancing healthcare through improved medical discovery, diagnostics, and care delivery. They have announced the opening of a new €4 million research & development (R&D) facility in Blackrock, Ireland. Plus, it will be investing an additional €30 million into expanding its manufacturing facility in Enniscorthy.

The new BD R&D facility will focus on the commercialisation of BD Evolve™ On-Body Injector, its first on-body injectable device. This device meets the growing demand for injectable drugs in the pharmaceutical industry. Additionally, the R&D facility will serve as the regional base for BD’s Sales, Technical Service, and Corporate Functional Support Teams.

The €30 million investment into the Enniscorthy manufacturing facility will house operations related to manufacturing a new medical technology from BD’s Peripheral Intervention business unit.